EODData

MEMBERSHIP REGISTER LOG IN

FRA, MFY: Mochida Pharmaceutical Co. Ltd

07 Nov 2025
LAST:

17.10

CHANGE:
 0.10		OPEN:
17.10		HIGH:
17.10		ASK:
0.00		VOLUME:
50
CHG(%):
0.59		PREV:
17.00		LOW:
17.10		BID:
0.00		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
07 Nov 2517.1017.1017.1017.1050
06 Nov 2517.0017.0017.0017.000
05 Nov 2516.8016.8016.8016.8050
04 Nov 2516.8016.8016.8016.8050
03 Nov 2516.2016.2016.2016.2050
31 Oct 2516.2016.2016.2016.2050
30 Oct 2516.2016.2016.2016.2050
29 Oct 2516.3016.3016.3016.3050
28 Oct 2516.6016.6016.6016.6050
27 Oct 2517.1017.1017.1017.1050

COMPANY PROFILE

Name:Mochida Pharmaceutical Co. Ltd
About:Mochida Pharmaceutical Co., Ltd. manufactures and sells pharmaceuticals and healthcare products in Japan. It offers pharmaceuticals products for the treatment of cardiovascular, obstetrics, gynecology, dermatology, psychiatry, and gastroenterology, including Lialda, Omvoh, and Cortiment for the treatment of ulcerative colitis; Goofice and Movicol for the treatment of chronic constipation; Epadel for hyperlidemia and arteriosclerosis obliterans; Urece for gout and hyperuricemia; Treprost for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; Atelec, a calcium channel blocker; Dinagest, an agent for endometriosis, adenomyosis, and dysmenorrhea; Lexapro, an antidepressant; Tamcet, an analgesic for chronic pain; Beselna, a therapeutic agent for condyloma acuminatum and actinic keratosis; and Heparin Sodium MOCHIDA anticoagulant agents. The company also develops mesalazine for the treatment of ulcerative colitis; tocilizumab for the treatment of rheumatoid arthritis; dotinurad for the treatment of gout and hyperuricemia; dienogest formulation for dysmenorrhea; treprostinil for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; and icosapent for hypertriglyceridemia. In addition, it develops medical devices, including dMD-001 that is used for the treatment of articular cartilage lesions; dMD-002, which is used for the treatment of cavernous nerve injury; and dMD-003 for post-operative adhesion. Further, the company engages in the development, production, distribution, sale, and marketing of skincare products. Mochida Pharmaceutical Co., Ltd. was founded in 1913 and is headquartered in Tokyo, Japan.
Sector:Healthcare
Address:7, Yotsuya 1-chome, Tokyo, Japan, 160-8515
Website:https://www.mochida.co.jp
ISIN:JP3922800002

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:18.00 
PEG Ratio:-3.48 
Price to Sales:0.01 
Price to Book:0.00 
Profit Margin:0.51 
Operating Margin:0.10 
Return on Assets:0.03 
Return on Equity:0.05 
DivYield:0.03 
Div/Share:80.00 
Revenue:599.09M 
EBITDA:62.0M 
Shares:35.45M 
Market Cap:606.2M 

TECHNICAL INDICATORS

MA5:16.781.9%
MA10:16.632.8%
MA20:16.821.7%
MA50:17.532.5%
MA100:17.502.4%
MA200:18.236.6%
STO9:100.00 
STO14:90.00 
RSI14:50.00
WPR14:-10.00 
MTM14:-0.10
ROC14:-0.01 
ATR:0.19 
Week High:17.100.0%
Week Low:16.205.6%
Month High:17.602.9%
Month Low:16.206.6%
Year High:22.4531.3%
Year Low:16.205.6%

RECENT SPLITS

Date Ratio
27 Mar 20192-1
26 Sep 20131-5

RECENT DIVIDENDS

Date Amount
29 Sep 2025$0.23
28 Mar 2025$0.23
27 Sep 2024$0.23
28 Mar 2024$0.23
28 Sep 2023$0.23
30 Mar 2023$0.23
29 Sep 2022$0.23
30 Mar 2022$0.28
29 Sep 2021$0.23
30 Mar 2021$0.23